Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma	Disease Attributes, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, lymphoma, neoplasm	Recruiting	Phase 1 / Phase 2	2026-06-18		NCT07502768

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fudan University	653
Rong Tao	5

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fudan University Shanghai Cancer Center	Shanghai	China	1

Clinical trials